Phillip A. Sharp's Insider Trades & SAST Disclosures
Phillip A. Sharp's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 11,250 Common Stock done at an average price of $131.2 . Disclosure was reported to the exchange on Jan. 23, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Phillip A. Sharp.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 131.21 per share. | 23 Jan 2025 | 11,250 | 11,250 (0%) | 0% | 131.2 | 1,476,113 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 275.00 per share. | 23 Jan 2025 | 11,250 | 0 (0%) | 0% | 275 | 3,093,750 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 11,250 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.25 per share. | 29 Feb 2024 | 30,000 | 30,000 (0%) | 0% | 59.3 | 1,777,500 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 151.43 per share. | 29 Feb 2024 | 13,557 | 3,438 (0%) | 0% | 151.4 | 2,052,937 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 150.60 per share. | 29 Feb 2024 | 13,005 | 16,995 (0%) | 0% | 150.6 | 1,958,553 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 153.62 per share. | 29 Feb 2024 | 1,906 | 617 (0%) | 0% | 153.6 | 292,800 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 152.40 per share. | 29 Feb 2024 | 915 | 2,523 (0%) | 0% | 152.4 | 139,446 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 156.54 per share. | 29 Feb 2024 | 516 | 0 (0%) | 0% | 156.5 | 80,775 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 154.07 per share. | 29 Feb 2024 | 101 | 516 (0%) | 0% | 154.1 | 15,561 | Common Stock |
| Vir Biotechnology Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 12,054 | 12,054 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 6,027 | 121,174 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.09 per share. | 15 Aug 2022 | 30,000 | 30,000 (0%) | 0% | 30.1 | 902,700 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 230.71 per share. | 15 Aug 2022 | 16,186 | 4,568 (0%) | 0% | 230.7 | 3,734,272 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 229.93 per share. | 15 Aug 2022 | 11,600 | 20,754 (0%) | 0% | 229.9 | 2,667,188 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 231.65 per share. | 15 Aug 2022 | 3,853 | 715 (0%) | 0% | 231.6 | 892,547 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.86 per share. | 15 Aug 2022 | 3,670 | 33,670 (0%) | 0% | 63.9 | 234,366 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 3,670 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 228.33 per share. | 15 Aug 2022 | 1,218 | 32,354 (0%) | 0% | 228.3 | 278,106 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 232.81 per share. | 15 Aug 2022 | 715 | 0 (0%) | 0% | 232.8 | 166,459 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 226.16 per share. | 15 Aug 2022 | 98 | 33,572 (0%) | 0% | 226.2 | 22,164 | Common Stock |
| Syros Pharmaceuticals Inc. | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Vir Biotechnology Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 12,810 | 12,810 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 6,405 | 115,147 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Vir Biotechnology Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 6,748 | 6,748 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 3,374 | 108,742 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Dec 2020 | 235,633 | 266,899 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Dec 2020 | 235,633 | 0 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.30 per share. | 25 Nov 2020 | 30,000 | 265,633 (0%) | 0% | 9.3 | 279,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2020 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 125.05 per share. | 25 Nov 2020 | 15,715 | 238,395 (0%) | 0% | 125.1 | 1,965,161 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 124.30 per share. | 25 Nov 2020 | 11,523 | 254,110 (0%) | 0% | 124.3 | 1,432,309 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 126.16 per share. | 25 Nov 2020 | 2,117 | 236,278 (0%) | 0% | 126.2 | 267,081 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Sale of securities on an exchange or to another person at price $ 127.44 per share. | 25 Nov 2020 | 645 | 235,633 (0%) | 0% | 127.4 | 82,199 | Common Stock |
| Alnylam Pharmaceuticals Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 4,581 | 4,581 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Vir Biotechnology Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2020 | 24,850 | 24,850 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges